11) Publication number:

0 397 859 A1

(12)

EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC

- (21) Application number: 88909824.0
- 2 Date of filing: 11.11.88
- (86) International application number: PCT/JP88/01141
- (87) International publication number: WO 89/04308 (18.05.89 89/11)

(a) Int. Cl.⁵: C07D 241/12, C07D 241/16, C07D 241/24, C07D 241/42, A61K 31/495

- Priority: 12.11.87 JP 286197/87
 12.11.87 JP 286198/87
 20.11.87 JP 293423/87
- Date of publication of application: 22.11.90 Bulletin 90/47
- Designated Contracting States: BE CH DE FR GB IT LI NL SE

- 71) Applicant: Terumo Kabushiki Kaisha No. 44-1, Hatagaya 2-chome Shibuya-ku Tokyo 151(JP)
- Inventor: SUWABE, Yasushi Terumo Kabushiki Kaisha 44-1, Hatagaya 2-chome Shibuya-ku

Tokyo 151(JP) Inventor: USHIJIMA, Hideto Terumo Kabushiki

Kaisha

44-1, Hatagaya 2-chome Shibuya-ku Tokyo 151(JP)

Inventor: HIJIKURO, Kohshi Terumo Kabushiki

Kaisha

44-1, Hatagaya 2-chome Shibuya-ku Tokyo 151(JP)

Inventor: SAKURAGI, Shiho Terumo Kabushiki

Kaisha

44-1, Hatagaya 2-chome Shibuya-ku Tokyo 151(JP)

Inventor: SUZUKI, Tadahiko Terumo Kabushiki

Kaisha

44-1, Hatagaya 2-chome Shibuya-ku

Tokyo 151(JP)

Inventor: AKITA, Yasuo 28-7, Akebonocho 3-chome Tachikawa-shi Tokyo 190(JP) Inventor: OHTA, Akihiro

10-8, Nishikoiwa 3-chome Edogawa-ku

Tokyo 133(JP)

Representative: Gillard, Marie-Louise et al Cabinet Beau de Loménie 55, Rue d'Amsterdam F-75008 Paris(FR)

EP 0 397 859 A1

9 PYRAZINE DERIVATIVES AND MEDICINAL PREPARATION CONTAINING SAME.

Pyrazine derivatives represented by general formula (I), wherein X represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a cyano group, R₁ represents a hydrogen atom, a lower alkyl group or a group of (a) (wherein X is as defined above), R₂ represents a hydrogen atom, a halogen atom or (a) (wherein X is as defined above), R₃ represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyano group, a naphthylmethyl group, a benzyl group or (b) (wherein R₄represents a hydrogen atom, a halogen atom or a lower alkylamino group), a carboxyl group or a lower alkoxycarbonyl group or, when taken together, R₂ and R₃ represent a cyclohexane ring or a benzene ring together with the carbon atoms to which they are bound, provided that the case where X represents a hydrogen atom, R₁ represents (a) (wherein X represents a hydrogen atom), and R₂ and R₃ represent hydrogen atoms and the case where X represents a hydrogen atom, R₁ represents a hydrogen atom, R₂ represents (a) (wherein X represents a hydrogen atom), and R₃ represents a methyl group are excluded. The pyrazine derivatives have a strong blood platelet agglutination depressing effect and a cyclooxygenase inhibiting effect. The above-described compounds are used as blood platelet agglutination inhibitor or anti-inflammatory agents.

TITLE

SPECIFICATION

Pyrazine derivatives and pharmaceutical preparations containing the same

Technical Field

5

10

15

20

This invention relates to novel pyrazine derivatives and pharmaceutical preparations containing the same.

The pyrazine derivative of the invention possess a potent platelet aggregation-inhibiting activity and are effective for preventing diseases caused by aggregation of the platelets such as thrombosis. As compounds having a cyclooxygenase-inhibiting activity are known, in general, to possess an antiinflammatory activity, the pyrazine derivatives of the invention having such inhibitory action find use as an antiinflammatory agent.

Technological Background

There have been known various substances which have platelet aggregation-inhibiting activities. Their activities, however, are so weak that development of improved agents is desired. There is also strong need for antithrombotic agents that will effectively prevent thromboses such as myocardial infarction and cerebral thrombosis which have recently become the majority of adult diseases.

On the other hand, a variety of pyrazine derivatives have recently been known such as, for example, 2,3-diphenylpyrazine described in Journal of Heterocyclic Chemistry, vol. 21, pp. 103-106. However, none of these pyrazine derivatives are known to possess a platelet aggregation-inhibiting activity.

As a result of extensive studies on pharmacological activities of novel pyrazine derivatives prepared by us, we have found that certain pyrazine derivatives possess excellent platelet aggregation-inhibitory and antiinflammatory activities and have completed the present invention.

Disclosure of the Invention

5

10

20

According to the present invention there are

15 provided pyrazine derivatives represented by the general formula (I)

$$\begin{array}{c|c}
X \\
N \\
R_1
\end{array}$$

$$\begin{array}{c}
N \\
R_3
\end{array}$$

$$(1)$$

wherein X represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a cyano group; R₁ represents a hydrogen atom, a lower alkyl group or a group having the formula -X in which X has the same meaning as

defined above; R2 represents a hydrogen atom, a halogen atom or a group having the formula $-\langle \bigcirc \rangle$ -X in which X has the same meaning as defined above; R_3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyano group, a naphthylmethyl group, a benzyl group having the formula $-CH_2$ in which R_4 represents a hydrogen atom, a halogen atom, or a lower alkylamino group, a carboxyl group or a lower alkoxycarbonyl group, or \mathbf{R}_2 and \mathbf{R}_3 together with the carbon atoms to which they are connected represent a cyclohexane ring or a benzene ring except for the case where X is a hydrogen atom, R_1 is a group having the formula $-\langle \bigcirc \rangle$ -x in which x is a hydrogen atom and R₂ and R₃ independently are a hydrogen atom or X is a hydrogen atom, R_1 is a hydrogen atom, R_2 is a group having the formula $\left\langle \bigcirc \right\rangle$ X in which X is a hydrogen atom and R_3 is a methyl group, and platelet aggregation-inhibiting agents and antiinflammatory agents containing said pyrazine derivatives.

5

10

15

Further according to the invention there are

20 provided a method for preventing thrombosis and a method for
treating inflammation which comprise administering an
effective amount of the above-mentioned pyrazine
derivatives.

In the definition of the substituents X, R_1 , R_2 and R_3 in the above formula (I), the lower alkyl group includes, for example, methyl, ethyl, propyl, isopropyl,

butyl and isobutyl, the halogen atom includes, for example, fluorine, chlorine and bromine, the lower alkoxy group includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy and isobutoxy, the lower alkyloxycarbonyl group includes, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl and isobutoxycarbonyl and the lower alkylamino group includes, for example, methylamino, ethylamino, propylamino, isopropylamino, butylamino and isobutylamino.

5

formula (II)

10 The compounds (I) in the present invention are preferably pyrazine derivatives having the formula:

1) pyrazine derivatives represented by the general

wherein R_4 and R_5 which may be the same or different independently represent a hydrogen atom or a lower alkyl group except for the case where R_4 represents a hydrogen atom and R_5 represents a methyl group;

2) pyrazine derivatives represented by the general
20 formula (III) or (IV)

wherein X represents a hydrogen atom, a halogen atom, a
lower alkyl group, a lower alkoxy group or a cyano group, or

5 3) pyrazine derivatives represented by the general formula (V)

$$\begin{array}{c|c}
X \\
\hline
N \\
R \\
7
\end{array}$$
(V)

wherein X represents a hydrogen atom, a cyano group or a lower alkoxy group, R_6 represents a hydrogen atom or a halogen atom and R_7 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyano group, a naphthylmethyl group, a benzyl group which may contain as the substituent a halogen atom or a lower alkylamino group, a carboxyl group or a lower alkyloxycarbonyl group.

5

10

15

The pyrazine derivatives of the invention having the above formula (I) are prepared depending upon the nature of R_1 , R_2 and R_3 as follows:

1) A pyrazine derivative of the formula (I) wherein R_1 and R_3 are independently a lower alkyl group and R_2 is a group having the formula -X is prepared by reacting a 2,6-dichloro-3,5-diphenylpyrazine derivative having the general formula (VI)

wherein X has the same meaning as defined above with a trilower alkylboron;

2) a pyrazine derivative of the formula (I) wherein

 R_1 is a group having the formula \bigcirc -X and R_2 and R_3 together with the carbon atoms to which they are connected form a cyclohexane ring or a benzene ring is prepared by heating a benzyl derivative having the general formula (VII)

$$C = 0$$

$$C = 0$$

$$V$$

$$V$$

5

10

wherein X has the same meaning as defined above and 1,2-diaminocyclohexane (VIII) or o-phenylenediamine (IX) in an appropriate organic solvent followed by heating with sulfur at 100-180°C

3) a compound of the formula (I) wherein R_1 is a group having the formula \bigcirc -X and both R_2 and R_3 are a hydrogen atom is prepared by heating a benzyl derivative

having the above-mentioned general formula (VII) and a 1,2-diamine having the formula (X)

$$\begin{array}{c|c}
H_2 & N \\
C & H_2 \\
C & H_2
\end{array}$$
(X)

in an appropriate organic solvent, for example, ethanol to give a dihydropyrazine derivative having the general formula (XI)

wherein X has the same meaning as defined above and subsequently heating it with sulfur at 100-180°C;

10 4) a compound of the formula (I) wherein R_1 is a group having the formula \bigcirc -X, R_2 is a hydrogen atom and R_3 is a naphthylmethyl group or a benzyl group which may be

substituted is prepared by reacting the above-mentioned dihydropyrazine derivative (XI) with naphthaldehyde or a benzaldehyde which may have as the substituent a halogen atom or a lower alkylamino group;

- group having the formula (I) wherein R₁ is a group having the formula (I) X, R₂ is a hydrogen atom or a halogen atom and R₃ is a halogen atom is prepared by oxidizing the pyrazine derivative (I) wherein R₂ and R₃ are independently a hydrogen atom with permaleic acid to give a mono- or di-N-oxide; and then halogenating it with a phosphorus oxyhalide; and
 - a compound of the formula (I) wherein R_1 is a group having the formula \bigcirc -X, R_2 is a hydrogen atom and R_3 is a cyano group is prepared by reacting a compound having the general formula (XII)

15

$$X$$
 N
 C
 N
 C
 N

wherein X has the same meaning as defined above with potassium cyanide in the presence of a palladium catalyst

such as tetrakis(triphenylphosphine)palladium.

5

20

25

Hydrolysis of said compound under alkaline conditions yields the compound (I) wherein \mathbf{R}_3 is a carboxyl group. Further alkylation of the same affords the compound (I) wherein \mathbf{R}_3 is a low alkyloxycarbonyl group.

As the pyrazine derivatives of the invention possess a platelet aggregation-inhibiting activity, they are effectively utilized as a platelet aggregation inhibition for the prevention of cerebral thrombosis and like diseases.

10 In addition, the pyrazine derivatives of the invention possess a cyclooxygenase-inhibiting activity and are also utilizable as an antiinflammatory agent. They may be administered at a dose between about 30-600 mg per day in adults, if necessary, divided into one to three doses. Any suitable route for administration may be chosen, oral administration being particularly desirable. Intravenous administration is also acceptable.

The compounds of the invention are formulated either alone or in admixture with pharmaceutical carriers or excipients by a conventional method into tablet, powder, capsule or granule. As examples of the carrier or excipient are mentioned calcium carbonate, calcium phosphate, starch, sucrose, lactose, talc, magnesium stearate and the like. In addition to the above-mentioned solid preparations, the compounds of the invention may also be formulated into liquid preparations such as oily suspension or syrup.

The compounds of the invention may also be stabilized in the form of inclusion in cyclodextrin.

The invention will more concretely be illustrated below by means of examples and pharmacological test examples.

Example 1

10

To a solution of 2,6-dichloro-3,5-diphenylpyrazine (840 mg, 3 mM), anhydrous potassium carbonate (1.24 g, 9 mM) and tetrakis(triphenylphosphine)palladium (348 mg, 0.3 mM) in anhydrous DMF (15 ml) was added a 15% Et₃B-hexane

- solution* (6 ml, 6 mM) in small portions at room
 temperature. The mixture was heated under reflux under
 argon stream for 12 hours. The solvent was distilled off
 under reduced pressure followed by addition of water (20
- ml). The mixture was extracted with methylene chloride, and the solvent is distilled off. There was obtained a brown viscous material, which was then subjected to medium pressure column chromatography on silica gel** (Column: Kieselgel 60, 230-400 mesh, manufactured by Merck, 20 mm x 200 mm; Solvent: Hexane-AcOEt=7:1). There was produced 50 mg of 2,6-diethyl-3,5-diphenylpyrazine (59%) as the first eluate.
 - * The solution manufactured by Kanto Kagaku K.K. used intact.
- 25 ** UVILOG, ALPC-100 (Oyo Bunko Kiki K.K.)

 Recrystallization from methanol gave 2,6-diethyl-

3,5-diphenylpyrazine as colorless needles, m.p. 90-91°C. Physical data of the product support the structure (1) below.

Elementary analysis: (C₂₀H₂₀N₂)

Calc'd: C, 83.29%; H, 6.99%; N, 9.80%

Found: C, 83.21%; H, 7.01%; N, 9.80%

MASS (m/z): 288 (molecular ion peak)

1H-NMR (CDCl₃) δ (ppm):

1.28(6H,t,J=7.5Hz), 2.90(4H,q,J=7.5Hz), 7.33-7.73(10H,m)

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

Example 2

15

As the second eluate in the column chromatography run in Example 1 was produced 2-ethyl-3,5-diphenylpyrazine (174 mg, 22%).

Recrystallization from methanol gave 2-ethyl-3,5-diphenylpyrazine as colorless needles, m.p. 86-87°C.

Physical data of the product support the structure (2) below.

Elementary analysis: $(C_{18}H_{16}N_2)$

Calc'd: C, 83.04%; H, 6.20%; N, 10.76%

Found: C, 83.12%; H, 6.32%; N, 10.79%

MASS (m/z): 260 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

1.27(3H,t,J=7.5Hz), 2.91(2H,q,J=7.5Hz),

7.54(8H,m), 8.07(2H,m), 8.90(1H,s)

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

Example 3

5

10

15

20

A solution of anisil (2.70 g, 10 mM) and 1,2-diaminocyclohexane (1.14 g, 10 mM) in ethanol (40 ml) was heated under reflux for 2 hours. After cooling, there were precipitated a small amount of yellow needles (anisil). The crystals were separated by suction filtration. The filtrate was removed by distillation under reduced pressure, and to the residue thus obtained was added sulfur (0.64 g). The mixture was heated at 150°C for 30 min. After cooling, the reaction residue was subjected to medium pressure column chromatography on silica gel* (Column: Kieselgel 60, 230-400 mesh, manufactured by Merck, 20 mm x 200 mm; Solvent:

Methylene chloride). There was obtained 1.24 g of 2,3-bis(p-methoxyphenyl)-5,6,7,8-tetrahydroquinoxaline (36%), m.p. 189-190°C (yellow prisms, recrystallized from acetonitrile). Physical data of the product support the structure (3) below.

* UVILOG ALPC-100 (Oyo Bunko Kiki K.K.)

Elementary analysis: $(C_{22}H_{22}N_2O_2)$

Calc'd: C, 76.27%; H, 6.40%; N, 8.09%

Found: C, 75.99%; H, 6.38%; N, 8.13%

10 MASS (m/z): 346 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

1.95(4H,m), 3.00(4H,m), 3.77(6H,s),

6.78(4H,d,J=9Hz), 7.35(4H,d,J=9Hz)

15 Example 4

A solution of anisil (10.8 g, 40 mM) and ophenylenediamine (5.32 g, 40 mM) in methanol was heated under reflux for 10 hours. After cooling, crystals precipitated were separated by filtration. The crystals were recrystallized from methanol to give 11.0 g of 2,3-bis(p-methoxyphenyl)quinoxaline (80%) as colorless needles, m.p. 151-153°C. Physical data of the product support the structure (4) below.

Elementary analysis: $(C_{22}H_{18}N_2O_2)$

Calc'd: C, 77.17%; H, 5.30%; N, 8.18%

Found: C, 77.03%; H, 5.31%; N, 8.16%

10 MASS (m/z): 342 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

3.78(6H,s), 6.83(4H,d,J=9Hz), 7.46(4H,d,J=9Hz),

7.67(2H,dd,J=6Hz,J=3Hz), 8.08(2H,dd,J=6Hz,J=3Hz)

15 Example 5

A solution of 2.57 g of 2,3-diphenyl-5,6-dihydropyrazine, 1.40 g of o-chlorobenzaldehyde and 0.672 g

of potassium hydroxide in 20 ml of methanol was allowed to react by heating under reflux for 1 hour. The methanol was distilled off from the reaction mixture under reduced To the residue was added 50 ml of water followed pressure. by extraction with three portions of ethyl acetate. organic layer of the extract was washed with water and dried over anhydrous sodium sulfate. The solvent was then distilled off under reduced pressure. The residue from the extract was subjected to column chromatography on silica There was produced a crude product from the fraction eluted with hexane-ethyl acetate (8:1). The crude product was recrystallized from a methanol-water mixture to yield 2.633 g of 2,3-diphenyl-5-(o-chlorobenzyl)pyrazine (74%) as colorless prisms, m.p. 112-114°C. Physical properties of the product support the structure (5) below.

Elementary analysis: $(C_{23}H_{17}ClN_2)$

5

10

15

Calc'd: C, 77.41%; H, 4.80%; N, 7.85%

Found : C, 77.13%; H, 4.81%; N, 7.83%

MASS (m/z): 356 (molecular ion peak)

20 1 H-NMR (CDCl₃) δ (ppm): 4.42(2H,s), 8.47(1H,s)

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

Example 6

5

10

The same procedures as in Example 5 were repeated using 2,3-diphenyl-5,6-dihydropyrazine (2.57 g) and m-chlorobenzaldehyde (1.40 g). There was obtained 3.338 g of 2,3-diphenyl-5-(m-chlorobenzyl)pyrazine (94%) as colorless prisms, m.p. 58-59°C (recrystallized from methanol-water). Physical data of the product support the structure (6) below.

Elementary analysis: $(C_{23}^{H}_{17}^{ClN}_{2})$

Calc'd; C, 77.41%; H, 4.80%; N, 7.85%

Found : C, 77.35%; H, 4.75%; N, 7.80%

MASS (m/z): 356 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm): 4.18(2H,s), 8.40(1H,s)

15 Example 7

The same procedures as in Example 5 were repeated using 2,3-diphenyl-5,6-dihydropyrazine (2.57 g) and p-chlorobenzaldehyde (1.40 g). There was obtained 3.358 g of 2,3-diphenyl-5-(p-chlorobenzyl)pyrazine (94%) as colorless

prisms, m.p. 105-106°C (recrystallized from isopropyl alcohol). Physical properties of the product support the structure (7) below.

Elementary analysis: $(C_{23}H_{17}ClN_2)$

Calc'd: C, 77.41%; H, 4.80%; N, 7.85%

Found: C, 77.54%; H, 4.80%; N, 7.86%

MASS (m/z): 356 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm): 4.20(2H,s), 8.40(1H,s)

10 Example 8

5

The same procedures as in Example 5 were repeated using 2,3-diphenyl-5,6-dihydropyrazine (2.57 g) and p-bromobenzaldehyde (1.85 g). There was obtained 3.87 g of 2,3-diphenyl-5-(p-bromobenzyl)pyrazine (97%) as colorless needles, m.p. 100-101°C (recrystallized from methanol). Physical data of the product support the structure (8) below.

Elementary analysis: $(C_{23}H_{17}BrN_2)$

Calc'd: C, 68.83%; H, 4.27%; N, 6.98%

Found: C, 68.84%; H, 4.24%; N, 6.97%

15

MASS (m/z): 401 (molecular ion peak) $^{1}\text{H-NMR (CDCl}_{3}) \ \delta \ (\text{ppm}): \ 4.23(2\text{H,s}), \ 8.48(1\text{H,s})$

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

Example 9

The same procedures as in Example 5 were repeated using 2,3-diphenyl-5,6-dihydropyrazine (2.57 g) and p-dimethylaminobenzaldehyde (1.49 g). There was obtained 3.36 g of 2,3-diphenyl-5-(p-dimethylaminobenzyl)pyrazine (92%) as colorless prisms, m.p. 80-82°C (recrystallized from methanol-water). Physical data of the product support the structure (9) below.

Elementary analysis: $(C_{25}H_{23}N_3)$

Calc'd: C, 82.16%; H, 6.34%; N, 11.50%

Found: C, 82.14%; H, 6.30%; N, 11.50%

MASS (m/z): 365 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

2.88(6H,s), 4.12(2H,s), 8.40(1H,s)

Example 10

5

The same procedures as in Example 5 were repeated using 2,3-diphenyl-5,6-dihydropyrazine (2.57 g) and 1-naphthaldehyde (1.56 g). There was obtained 3.30 g of 2,3-diphenyl-5-(1-naphthyl)methylpyrazine (89%) as colorless prisms, m.p. 91-92°C (recrystallized from methanol-water). Physical data of the product support the structure (10) below.


10 Elementary analysis: $(C_{27}^{H_{20}N_2})$

Calc'd: C, 87.06%; H, 5.41%; N, 7.52%

Found: C, 86.96%; H, 5.43%; N, 7.50%

MASS (m/z): 372 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm): 4.70(2H,s), 8.30(1H,s)



$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

Example 11

g, 5.6 mM) was mixed with phosphorus oxychloride (20 ml),
and the mixture was allowed to react by heating under reflux
for one hour. After cooling, the reaction mixture was
poured onto ice water, subsequently made basic with
potassium carbonate and extracted with methylene chloride.
After the solvent was distilled off, there was a pale yellow
extraction residue. The residue was subjected to column
chromatography on silica gel (Wakogel C-200, 32 g; Solvent:
A benzene-AcOEt mixture). There was obtained as the first
eluate 1.50 g of 2,3-bis(p-methoxyphenyl)-5,6-dichloropyrazine (78%).

Recrystallization from hexane afforded 2,3-bis(p-methoxyphenyl)-5,6-dichloropyrazine as colorless needles,
m.p. 120-121°C. Physical data of the product support the

structure (11) below.

5

Elementary analysis: $(C_{18}H_{14}Cl_2N_2O_2)$

Calc'd: C, 59.85%; H, 3.91%; N, 7.76%

Found : C, 60.02%; H, 3.88%; N, 7.79%

MASS (m/z): 360 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

3.77(6H,s), 6.83(4H,d,J=7.5Hz), 7.43(4H,d,J=7.5Hz)

$$\begin{array}{c|c} C H_3 & O \\ \hline \\ N \\ \hline \\ C H_3 & O \end{array}$$

Example 12

2,3-Bis(p-methoxyphenyl)pyrazine dioxide (3.92 g,
12.7 mM) was mixed with phosphorus oxychloride (20 ml), and
the mixture was allowed to react by heating under reflux for
30 min. After cooling, the reaction mixture was poured onto
ice water, and subsequently made alkaline with potassium
carbonate. There was then precipitated a yellowish orange
solid which was recovered by filtration and subjected to
column chromatography on silica gel (Wakogel C-200, 70 g;

Solvent: Hexane-methylene chloride=1:1). There was obtained 2.82 g of 2,3-bis(p-methoxyphenyl)-5-chloropyrazine (76%), m.p. 127-128°C (pale yellow prisms, recrystallized from ethanol). Physical data of the product support the structure (12) below.

Elementary analysis: (C₁₈H₁₅ClN₂O₂)

Calc'd: C, 66.17%; H, 4.63%; N, 8.57%

Found: C, 65.91%; H, 4.63%; N, 8.60%

MASS (m/z): 326 (molecular ion peak)

1H-NMR (CDCl₃) \$ (ppm):

3.77(6H,s), 6.77(4H,d,J=7Hz), 7.33(2H,d,J=7Hz),

7.37(2H,d,J=7Hz), 8.42(1H,s)

Example 13

5

10

A solution of 2,3-bis(p-methoxyphenyl)-5chloropyrazine (3.27 g, 10 mM), potassium cyanide (975 mg,
15 mM) and tetrakis(triphenylphosphine)palladium (580 mg,
0.5 mM) in anhydrous DMF (50 ml) was heated under reflux for
4 hours under argone stream. The solvent was removed by
20 distillation under reduced pressure. To the residue was

added water (100 ml), and the mixture was extracted with methylene chloride. The solvent was distilled off to give a dark brown viscous material, which was then subjected to medium pressure column chromatography on silica gel*

5 (Column: Kieselgel 60, 230-400 mesh, manufactured by Merck, 20 mm x 200 mm; Solvent: Hexane-AcOEt=4:1). There was obtained 2.66 g of 2,3-bis(p-methoxyphenyl)-5-cyanopyrazine (84%), m.p. 110-112°C (pale yellow needles, recrystallized from ethanol). Physical data of the product support the

* UVILOG ALPC-100(Oyo Bunko Kiki K.K.)

Elementary analysis: $(C_{19}H_{15}N_3O_2)$

Calc'd: C, 71.91%; H, 4.76%; N, 13.24%

Found: C, 71.89%; H, 4.63%; N, 13.27%

MASS (m/z): 317 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

3.77(6H,s), 6.80(4H,d,J=9Hz), 7.43(2H,d,J=9Hz),

7.45(2H,d,J=9Hz), 8.70(1H,s)

 $IR(KBr) cm^{-1}: 2260 (C=N)$

20

Example 14

To a solution of 2,3-bis(p-methoxyphenyl)-5cyanopyrazine (2.0 g, 6.3 mM) in a mixture of methanol (40 ml) and 1,4-dioxane (30 ml) was added a 20% aqueous solution of sodium hydroxide. The mixture was heated under reflux 5 for 4 hours. The solvent was distilled off under reduced pressure. The residue was neutralized with a 5% hydrochloric acid solution followed by extraction with methylene chloride. The solvent was distilled off to give a The crude product was recrystallized from crude product. 10 ethanol to afford 2.07 g of 2,3-bis(p-methoxyphenyl)pyrazine-5-carboxylic acid (95%) as colorless needles, m.p. 234-235°C. Physical data of the product support the structure (14).

15 Elementary analysis: $(C_{19}^{H}_{16}^{N}_{2}^{O}_{4})$

Calc'd: C, 67.85%; H, 4.80%; N, 8.33%

Found: C, 67.69%; H, 4.85%; N, 8.34%

MASS (m/z): 336 (molecular ion peak)

 $IR(KBr) cm^{-1}: 1690$

20

Example 15

10

15

20

To a solution of 2,3-bis(p-methoxyphenyl)pyrazine-5-carboxylic acid (336 mg, 1mM) in methanol (5 ml) was added concentrated sulfuric acid (0.1 ml). The mixture was heated under reflux for 3 hours. The solvent was distilled off under reduced pressure. To the residue was added water (15 ml) followed by neutralization with potassium carbonate. The resulting mixture was extracted with methylene chloride. The solvent was distilled off to give a crude product. The crude product was recrystallized from methanol to afford 320 mg of 2,3-bis(p-methoxyphenyl)pyrazine-5-carboxylic acid (91%) as colorless needles, m.p. 140-141°C. Physical data of the product support the structure (15) below.

Elementary analysis: $(C_{20}H_{18}N_2O_4)$

Calc'd: C, 68.56%; H, 5.18%; N, 8.00%


Found: C, 68.40%; H, 5.11%; N, 7.93%

MASS (m/z): 350 (molecular ion peak)

 1 H-NMR (CDCl₃) δ (ppm):

3.77(6H,s), 3.97(3H,s), 6.78(4H,d,J=9Hz),

7.43(4H,d,J=9Hz), 9.12(1H,s)



Pharmacological Test Examples
(Platelet Aggregation-Inhibiting Action)

5

10

.

Blood was drawn from the carotid artery of a rabbit using a syringe containing 1/10 volume of a 3.8% solution of sodium citrate. The blood was centrifuged to obtain platelet-rich plasma (PRP: 5×10^5 cells/ μ l).

In a cuvette were placed 200 μ l of said PRP and 25 μ l of a physiological saline solution. The cuvette was set on an aggregometer and warmed at 37°C for 2 min. Into the cuvette was then added 1.25 μ l of an ethanol solution of a pyrazine derivative to be tested. After incubated for 3 min., a solution of a platelet-aggregation inducer, arachidonic acid or collagen, was added thereto.

Measurements were made for platelet aggregation using an aggregometer (Hematracer IV; Niko Biosciences K.K.). In Table 1 is shown the concentration required for 50% inhibition of the platelet aggregation caused by arachidonic acid (80 μ M) or collagen (15 μ g/ml). Acetylsalicylic acid

was used as a comparison.

5

10

As shown in Table 1, the pyrazine derivatives of the invention were found to possess a marked platelet aggregation-inhibiting activity. The pyrazine derivatives not shown in Table 1 were also found to possess a similar activity. The 50% inhibitory concentration as shown in the table means the concentration of the solution of a pyrazine derivative required for inhibiting the aggregation of platelets by introducing said pyrazine derivative when the platelet aggregation in the absence of any pyrazine derivative of the invention is taken as 100%.

Table 1 Platelet aggregation-inhibiting activity

$$R_1$$
 R_2
 R_3

50% aggregation-inhibitory

15		Substitu	ent	· · · · · · · · · · · · · · · · · · ·	concentration (mole)		
	<u> </u>	R1	R2_	_R3_	Arachidonic acid	Collagen	
	Н	Н	$\langle \bigcirc \rangle$	с ₂ н ₅	6.0×10^{-6}	1.9×10^{-5}	
	Н	с ₂ н ₅	$\langle \overline{0} \rangle$	с ₂ н ₅	1.7×10^{-6}	3.9×10^{-7}	
	сн ₃ 0	-O>OCH3	X		1.5×10^{-8}	2.4×10^{-8}	
20	сн ₃ 0	-{O}-OCH ₃	X		3.8×10^{-8}	9.8 x 10 ⁻⁹	

Table 1 Platelet aggregation-inhibitory concentration (cont'd)

	Substituent				50% aggregation-inhibitory concentration (mole)		
5	<u>x</u>	R1	R ₂	R3	Arachidonic acid	Collagen	
	Н	-(0)	Н	-CH ₂ -O-N(CH ₃) ₂	4.4×10^{-6}	3.6×10^{-5}	
	Н	√ ○	Н	-CH ₂	4.5×10^{-6}	4.4 x 10 ⁻⁵	
	Н	-(0)	Н	-CH ₂ -Oj	8.2×10^{-5}	3.4×10^{-5}	
	Н	$\langle \bigcirc \rangle$	Н	-CH ₂ -Cl	1.6×10^{-5}	1.0×10^{-4}	
10	Н	$\langle \bigcirc \rangle$	Н	-CH ₂ -O-Br	8.4×10^{-5}	7.4×10^{-5}	
	Н	-{0}	Н	-CH ₂ -O	4.3×10^{-5}	3.1×10^{-5}	





Table 1 Platelet aggregation-inhibitory concentration (cont'd)

		Substitue	nt		50% aggregation-inhibitory concentration (mole)		
5	X	R ₁	_R ₂ _	<u>R3</u>	Arachidonic acid	Collagen	
	-осн ₃	-{O}-осн ₃	Н	-CN	2.4×10^{-8}	1.5 x 10 ⁻⁸	
	-OCH ₃	-O-OCH3	Н	- COOH	2.6×10^{-7}	5.0×10^{-6}	
	-OCH ₃	-(O)-OCH ₃	Н	-соосн ₃	3.0×10^{-9}	1.3×10^{-7}	
	-осн ₃	-(O)-OCH3	į H	-Cl	3.8×10^{-9}	9.8 x 10 ⁻⁹	
10	-осн ₃	-O-OCH3	Cl	-Cl	1.4×10^{-8}	2.2×10^{-7}	
	-CN	-{O}-CN	Н	-CH ₃	1.0×10^{-6}	1.0×10^{-6}	



(Cyclooxygenase-inhibiting Activity)

からからのという をはなの様のかった

こういのかっきょうから このない 関係の からかい あっという こうない 高端

25

In a centrifuge tube was collected 9 volumes of blood from the carotid artery of a rabbit per volume of a 3.8% solution of sodium citric acid contained therein using Platelet-rich plasma was obtained by 5 centrifugation. To the platelet-rich plasma was added a 77 mM solution of EDTA in a volume of 1/10 per volume of said After mixing thoroughly, the mixture was subjected to centrifugation at 2500 r.p.m. at room temperature for 10 The supernatant was discarded, and the platelets were 10 suspended in approximately 3 ml of a wash (134 mM of sodium chloride, 15 mM of trisaminomethane, 1 mM of EDTA and 5 mM of D-glucose dissolved in distilled water with a pH adjusted to 7.4 with 1N-hydrogen chloride), and the suspension was centrifuged at 2000 rpm at room temperature for 10 min. 15 supernatant was discarded, and the precipitated platelets were suspended in a 1/15 M phosphate buffer solution at pH 8.0 to adjust the number of the platelets to 6-8 x 10^5 cells/ μ l.

The washed platelets thus produced were used as an enzyme source for cyclooxygenase.

In a test tube with a ground stopper were placed 3 μg of arachidonic acid and 0.2 μCi (1 μg) of $^{14}C\text{-labeled}$ arachidonic acid (in toluene solution), to which was added one drop of a propylene glycol/ethanol mixture (1:3 in volume). The toluene and the ethanol were evaporated under nitrogen gas stream. To the test tube was added 50 μl of a

test solution and then 500 μl of the washed platelets followed by reaction at 37°C for 3 min.

The reaction mixture was adjusted to pH 2-3 by the addition of 3 drops of 0.5 N-hydrogen chloride while cooling with ice. To the resulting mixture was added 2 ml of ethyl acetate, and extraction was made by shaking for 10 min. followed by centrifugation at 2500 rpm at 4°C for 10 min.

The supernatant was transferred to a flask and concentrated. The residue was dissolved in 100 μ l of ethanol, and the entire solution was spotted on a thin layer plate of silica gel (60F 254 manufactured by Merck).

Development was made with a developing solvent (chloroform/methanol/acetic acid/water = 90:8:1:0.8) by approximately 18 cm, and then the inhibiting activity was determined by measuring sum of the radioactivities of prostaglandin E_2 , prostaglandin D_2 and HHT by a radiochromatogram scanner. The result is shown in Table 2. The pyrazine derivatives of the invention not shown in Table 2 were also found to possess a similar activity.

Table 2 Cyclooxygenase-inhibiting activity

	Substitue	nt	50% inhibitory concentration	
X	Rl	R ₂	R3	(mole)
-och ₃	-{O}-осн ₃	Н	-CN	5×10^{-6}

(Acute Toxicity)

10

15

20

25

An acute toxicity test was conducted in male ICR

mice (5 week-old) by oral administration. LD_{50} values were 300 mg/kg or higher for all of the pyrazine derivatives of the invention tested thereby demonstrating high safety. (Industrial Applicability)

According to the invention there are provided novel pyrazine derivatives and pharmaceutical preparations containing the same.

5

10

15

As said compounds of the invention remarkably inhibit the platelet aggregation induced by arachidonic acid or collagen, they can be used as a preventive agent for diseases caused by platelet aggregation, particularly for thromboses in which platelet aggregation participates such as myocardial infarction, ischemic attack after cerebral hemorrhage and cerebral infarct.

The above-mentioned compounds of the invention also have a cyclooxygenase-inhibiting activity and can be used as an antiinflammatory agent.

Therefore, the present invention is utilizable in a field of pharmaceutical industries.

Claim

1) A pyrazine derivative represented by the general formula (I)

wherein X represents a hydrogen atom, a halogen atom, a 5 lower alkyl group, a lower alkoxy group or a cyano group; R_1 represents a hydrogen atom, a lower alkyl group or a group having the formula - X in which X has the same meaning as defined above; R₂ represents a hydrogen atom, a halogen atom or a group having the formula $-\langle \bigcirc \rangle$ -X in which X has the same 10 meaning as defined above; R_3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyano group, a naphthylmethyl group, a benzyl group having the formula $-CH_2$ in which R_4 represents a hydrogen atom, a halogen atom, or a lower alkylamino group, a carboxyl group 15 or a lower alkoxycar bonyl group, or R_2 and R_3 together with the carbon atoms to which they are connected represent a cyclohexane ring or a benzene ring except for the case where ${\tt X}$ is a hydrogen atom, ${\tt R}_1$ is a group having the formula

- -X in which X is a hydrogen atom and R₂ and R₃ independently are a hydrogen atom or X is a hydrogen atom, R₁ is a hydrogen atom, R₂ is a group having the formula -X in which X is a hydrogen atom and R₃ is a methyl group.
- 2) A pyrazine derivative according to Claim 1 represented by the general formula (II)

5

15

$$\begin{array}{c|c}
N & & \\
\hline
 & N & \\
R_4 & & \\
\end{array}$$
(II)

wherein $\rm R_4$ and $\rm R_5$ which may be the same or different independently represent a hydrogen atom or a lower alkyl group except for the case where $\rm R_4$ represents a hydrogen atom and $\rm R_5$ represents a methyl group.

3) A pyrazine derivative according to Claim 1 represented by the general formula (III) or (IV)

$$\chi$$

wherein X represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a cyano group.

4) A pyrazine derivative according to Claim 1 represented by the general formula (V)

5

$$\begin{array}{c}
X \\
N \\
N
\end{array}$$

$$\begin{array}{c}
R \\ 6 \\
N
\end{array}$$

$$X$$

$$\begin{array}{c}
X \\
R \\
7
\end{array}$$

wherein X represents a hydrogen atom, a cyano group or a lower alkoxy group, R₆ represents a hydrogen atom or a halogen atom and R₇ represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyano group, a naphthylmethyl group, a benzyl group which may contain as the substituent a halogen atom or a lower alkylamino group, a carboxyl group or a lower alkyloxycarbonyl group.

- 5) A platelet aggregation-inhibiting agent comprising the pyrazine derivative according to Claim 1.
- 6) An antiinflammatory agent comprising the pyrazine derivative according to Claim 1.
- 7) A method for preventing thrombosis which comprises administering an effective amount of the pyrazine derivative according to Claim 1 to patients possibly afflicted with said disease.
- 8) A method for treating inflammation which comprises
 10 administering an effective amount of the pyrazine derivative
 according to Claim 1 to patients afflicted with said
 symptom.
- 9) Use of the pyrazine derivative according to Claim
 1 for the preparation of a platelet aggregation-inhibiting
 15 agent.
 - 10) Use of the pyrazine derivative according to Claim
 1 for the preparation of an antiinflammatory agent.

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP 88/01141

		THE STATE OF THE S	/JP 00/ULL41		
	ON OF SUBJECT MATTER (if several classif				
According to International Int.Cl ⁴	tional Patent Classification (IPC) or to both Nati C07D241/12, 241/16, A61K31/495	ional Classification and IPC 241/24, 241/42,			
I. FIELDS SEARC	HED				
	Minimum Documen	ntation Searched ⁷			
lassification System	1	Classification Symbols			
	C07D241/10-241/16,	241/24 241/26-241/	4.2		
IPC	A61K/495	241/24, 241/30-241/	42,		
	Documentation Searched other t to the Extent that such Documents	han Minimum Documentation are Included in the Fields Searched ^a			
	CONSIDERED TO BE RELEVANT 9 Ition of Document, 11 with indication, where app	regulate of the relevant pageages 12	Relevant to Claim No. 13		
	The second secon		<u>' </u>		
d'A	Bl, 46-12726 (Société quitaine)		e 1 - 2		
L A	pril 1971 (01. 04. 71)	(Family: none)			
9 N	A, 49-117480 (Koei Ch ovember 1974 (09. 11. mily: none)		1		
	JP, A, 58-43961 (Ube Industries, Ltd.) 1, 5-10 14 March 1983 (14. 03. 83) (Family: none)				
	JP, A, 61-129171 (Ube Industries, Ltd.) 17 June 1986 (17. 06. 86) (Family: none)				
20	A, 61-212522 (Terumo September 1986 (20. 09 mily: none)		1, 4-10		
15	A, 61-257978 (Suntory November 1986 (15. 11. , A, 4755514 &EP, A, 2	86)	1, 5-10		
"A" document def considered to earlier document wh which is cited citation or oth document references document put	s of cited documents: 10 ining the general state of the art which is not be of particular relevance ent but published on or after the international inch may throw doubts on priority claim(s) or to establish the publication date of another er special reason (as specified) erring to an oral disclosure, use, exhibition or elished prior to the international filing date but priority date claimed	"T" later document published after the priority date and not in conflict with understand the principle or theory document of particular relevance; the considered novel or cannot be inventive step document of particular relevance; the considered to involve an inventive combined with one or more of combination being obvious to a perfect of the same particular relevance; the combination being obvious to a perfect of the same particular relevance; the combination being obvious to a perfect of the same particular relevance.	In the application but cited to underlying the invention he claimed invention cannot be considered to involve as the claimed invention cannot be called invention cannot be step when the document, such documents, such step in the art		
IV. CERTIFICATION	ON				
Date of the Actual C	completion of the international Search	Date of Mailing of this International Se	arch Report		
	1, 1989 (01. 02. 89)	February 13, 1989	(13. 02. 89)		
International Search Japane	ng Authority se Patent Office	Signature of Authorized Officer			

	·	·
FURTHER	INFORMATION CONTINUED FROM THE SECOND SHEET	
x	JP, A, 62-5970 (Terumo Corporation) 12 January 1987 (12. 01. 87) &EP, A, 194686	1, 4-10
x	JP, A, 62-89669 (Ube Industries, Ltd.) 24 April 1987 (24. 04. 87) (Family: none)	. 1
Х	<pre>JP, A, 62-234072 (Ube Industries, Ltd.) 14, October 1987 (14. 10. 87) (Family: none)</pre>	1
P	JP, A, 62-270564 (Terumo Corporation) 24 November 1987 (24. 11. 87) &EP, A, 194686	1, 4-10
V.	SERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1	
	national search report has not been established in respect of certain claims under Article 17(2) (a) f	
I. Clai	m numbers, because they relate to subject matter not required to be searched by the	is Authority, namely:
	·	
ندای 🗍 ی	m numbers because they relate to parts of the international application that do not co	mply with the prescribed
requ	irements to such an extent that no meaningful international search can be carried out, specif	fically:
	,	
3. Clai	m numbers, because they are dependent claims and are not drafted in accordance w tences of PCT Rule 6.4(a).	vith the second and third
	SERVATIONS WHERE UNITY OF INVENTION IS LACKING 2	
This Inter	national Searching Authority found multiple inventions in this international application as follo	ows:
1 🗀 🔥	all required additional search fees were timely paid by the applicant, this international search re	port covers all searchable
clai	ms of the international application.	p
2. As o	only some of the required additional search fees were timely paid by the applicant, this international se claims of the international application for which fees were paid, specifically claims:	search report covers only
tno	se claims of the international application for which less were paid, specifically claims.	
	•	
3. No	required additional search fees were timely paid by the applicant. Consequently, this international se invention first mentioned in the claims; it is covered by claim numbers:	earch report is restricted to
uie	medicion mat mondored in the claims, in a contract of the management	
	all searchable claims could be searched without effort justifying an additional fee, the International S ite payment of any additional fee.	earching Authority did not
	on Protest	
The	additional search fees were accompanied by applicant's protest.	
	protest accompanied the payment of additional search fees.	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET							
P	JP, A, 63-267765 (Ube Industries, Ltd.) 4 November 1988 (04. 11. 88) (Family: none)	1					
Х	JP, A, 49-124004 (Tamura Yukimitsu) 27 November 1974 (27. 11. 74) (Family: none)	1					
	·						
V. OBS	SERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1						
This intern	ational search report has not been established in respect of certain claims under Article 17(2) (a) fo	or the following reasons:					
1. Clair	n numbers, because they relate to subject matter not required to be searched by thi	s Authority, namely:					
	¥.						
2. Clair	n numbers, because they relate to parts of the international application that do not cor irements to such an extent that no meaningful international search can be carried out, specifi	nply with the prescribed cally:					
	·						
	n numbers, because they are dependent claims and are not drafted in accordance wi ences of PCT Rule 6.4(a).	th the second and third					
VI OB	SERVATIONS WHERE UNITY OF INVENTION IS LACKING ²						
This Intern	national Searching Authority found multiple inventions in this international application as follo	ws:					
	ill required additional search fees were timely paid by the applicant, this international search rep ns of the international application.	ort covers all searchable					
2. As o	nly some of the required additional search fees were timely paid by the applicant, this international e claims of the international application for which fees were paid, specifically claims:	search report covers only					
3. No r	equired additional search fees were timely paid by the applicant. Consequently, this international seinvention first mentioned in the claims; it is covered by claim numbers:	arch report is restricted to					
4. As a invit	Il searchable claims could be searched without effort justifying an additional fee, the International Se le payment of any additional fee. n Protest	earching Authority did not					
☐ The	additional search fees were accompanied by applicant's protest.						
I □ No	protest accompanied the payment of additional search fees.						

FURTHER	FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET					
P	JP, A, 63-10768 (Terumo Corporation) 18 January 1988 (18. 01. 88) (Family: none)	1, 4-10				
P	JP, A, 63-91377 (Ube Industries, Ltd.) 22 April 1988 (22. 04. 88) (Family: none)	1				
x	JP, A, 59-144770 (Ube Industries, Ltd.) 18 August 1984 (18. 08. 84) (Family: none)	1				
P	JP, A, 63-227551 (Ube Industries, Ltd.) 21 September 1988 (21. 09. 88) (Family: none)	1				
V. ☐ OB	SERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1					
		a the fallowing recognit				
	national search report has not been established in respect of certain claims under Article 17(2) (a) for numbers , because they relate to subject matter not required to be searched by thi					
2. Claim numbers, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:						
	m numbers, because they are dependent claims and are not drafted in accordance with the series of PCT Rule 6.4(a).	ith the second and third				
VI. ☐ OB	SERVATIONS WHERE UNITY OF INVENTION IS LACKING ²					
This Inter	national Searching Authority found multiple inventions in this international application as follo	ws:				
	all required additional search fees were timely paid by the applicant, this international search rep					
clair	ms of the international application.					
2. As o	only some of the required additional search fees were timely paid by the applicant, this international se claims of the international application for which fees were paid, specifically claims:	search report covers only				
3. No the	required additional search fees were timely paid by the applicant. Consequently, this international se invention first mentioned in the claims; it is covered by claim numbers:	arch report is restricted to				
invi Remark o	all searchable claims could be searched without effort justifying an additional fee, the International So te payment of any additional fee. on Protest	earching Authority did not				
, –	additional search fees were accompanied by applicant's protest.					
I I No	protest accompanied the payment of additional search fees.					